Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | Why should elderly AML patients take part in clinical trials?

Mhairi Copland • 27 Mar 2017
BSH 2017
Acute Myeloid Leukemia

Mhairi Copland, PhD, MB, ChB, MRCP, FRCPath, from the University of Glasgow, Glasgow, UK, discusses why elderly acute myeloid leukemia (AML) patients should be encouraged to participate in clinical trials at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She speaks about the low proportion of patients over 75 who take part in clinical trials, and emphasizes the need to include these patients if new treatments are to be developed.

More from Mhairi Copland

3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
1:36
The importance of improving treatment-free remission in patients with CML
Mhairi Copland • 29 Sep 2022
1:12
The challenges associated with long-term TKI use in patients with CML
Mhairi Copland • 29 Sep 2022
2:29
Treatment options for patients with CML
Mhairi Copland • 29 Sep 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals